WO2011008117A3 - The use of a sirna oligonucleotide - Google Patents
The use of a sirna oligonucleotide Download PDFInfo
- Publication number
- WO2011008117A3 WO2011008117A3 PCT/PL2010/000059 PL2010000059W WO2011008117A3 WO 2011008117 A3 WO2011008117 A3 WO 2011008117A3 PL 2010000059 W PL2010000059 W PL 2010000059W WO 2011008117 A3 WO2011008117 A3 WO 2011008117A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sirna oligonucleotide
- wnt
- nucleotides
- beta
- disclose
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
We disclose the use of a siRNA oligonucleotide comprising at least 19 nucleotides, complementary to the target mRNA encoding proteins of the WNT/beta-catenin pathway, in the production of a drug for systemic administration in the treatment of cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL388513A PL388513A1 (en) | 2009-07-12 | 2009-07-12 | Application of siRNA oligonucleotide |
PLPL388513 | 2009-07-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011008117A2 WO2011008117A2 (en) | 2011-01-20 |
WO2011008117A3 true WO2011008117A3 (en) | 2011-11-17 |
Family
ID=43450014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/PL2010/000059 WO2011008117A2 (en) | 2009-07-12 | 2010-07-12 | The use of a sirna oligonucleotide |
Country Status (2)
Country | Link |
---|---|
PL (1) | PL388513A1 (en) |
WO (1) | WO2011008117A2 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008109518A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting wnt gene expression and uses thereof |
US20090081282A1 (en) * | 2007-09-21 | 2009-03-26 | Korea University Industrial & Academic Collaboration Foundation | Pharmaceutical composition for treating cancer |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL378857A1 (en) | 2006-01-31 | 2007-08-06 | Celon Pharma Spółka Z Ograniczoną Odpowiedzialnością | Double twisted oligonucleotides interfering with mRNA of gene WNT1 (siRNA) used in order to inhibit polypheration of tumour cells |
-
2009
- 2009-07-12 PL PL388513A patent/PL388513A1/en not_active Application Discontinuation
-
2010
- 2010-07-12 WO PCT/PL2010/000059 patent/WO2011008117A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008109518A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting wnt gene expression and uses thereof |
US20090081282A1 (en) * | 2007-09-21 | 2009-03-26 | Korea University Industrial & Academic Collaboration Foundation | Pharmaceutical composition for treating cancer |
Non-Patent Citations (1)
Title |
---|
P PU ET AL: "Downregulation of Wnt2 and [beta]-catenin by siRNA suppresses malignant glioma cell growth", CANCER GENE THERAPY, vol. 16, no. 4, 1 April 2009 (2009-04-01), pages 351 - 361, XP055001526, ISSN: 0929-1903, DOI: 10.1038/cgt.2008.78 * |
Also Published As
Publication number | Publication date |
---|---|
WO2011008117A2 (en) | 2011-01-20 |
PL388513A1 (en) | 2011-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009043353A3 (en) | Micromirs | |
IL245050A0 (en) | Optimized fc variants, pharmaceutical compositions and medicaments comprising the same, and methods for their production | |
MX356625B (en) | Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell. | |
IL219530A (en) | Substituted 4-aminocyclohexane compounds, medications comprising said compounds and their use for the production of medications | |
WO2011113030A3 (en) | Human cancer micro-rna expression profiles predictive of chemo-response | |
ZA201104620B (en) | Zaleplon gastroretentive drug delivery system | |
WO2013074974A3 (en) | Modified rnai agents | |
AP2011005975A0 (en) | Thieno [2,3-B] pyridine derivatives as viral replication inhibitors. | |
EP3698631A3 (en) | Methods of delivering oligonucleotides to immune cells | |
EP2379597B8 (en) | Egfr-homing double-stranded rna vector for systemic cancer treatment | |
EP2245039A4 (en) | Optimized methods for delivery of dsrna targeting the pcsk9 gene | |
IL195245A0 (en) | Substituted prolinamides, production thereof and their use as drugs | |
EP2273975B8 (en) | Pharmaceutical solutions, process of preparation and therapeutic uses | |
WO2012107908A3 (en) | Nts-polyplex nanoparticles system for gene therapy of cancer | |
WO2009129387A3 (en) | Cationic lipids and uses thereof | |
WO2011143201A3 (en) | Ratiometric combinatorial drug delivery | |
WO2011009938A3 (en) | Stambomycin and derivatives, their production and their use as drugs | |
ZA201103727B (en) | Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as medicine | |
EP2298282A4 (en) | Combination of drugs having different physical properties into single dosage form | |
HK1176964A1 (en) | Novel therapeutic rna interference technology targeted to the pdx-1 oncogene in pdx-1 expressing neuroendocrine tumors pdx-1 pdx-1 rna | |
WO2009071082A9 (en) | Rna antagonist compounds for the modulation of pik3ca expression | |
AP2010005389A0 (en) | Nanoparticle carriers for drug administration and process for producing same. | |
WO2010007522A8 (en) | Rna antagonists targeting gli2 | |
EP2533763C0 (en) | Dermatological, pharmaceutical composition suitable for oligonucleotides | |
IL212603A0 (en) | Combined drug administration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10747328 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10747328 Country of ref document: EP Kind code of ref document: A2 |